Literature DB >> 1939196

Abnormal tau proteins from Alzheimer's disease brains. Purification and amino acid analysis.

W K Liu1, H Ksiezak-Reding, S H Yen.   

Abstract

Abnormal tau proteins (PHF-tau) were isolated from Alzheimer's disease brains by treatment of paired helical filament enriched-fractions with perchloric acid and boiling of the acid precipitable fraction with beta-mercaptoethanol. These proteins were purified further by a second perchloric acid treatment. The purified PHF-tau proteins were soluble in buffers devoid of sodium dodecyl sulfate. However, they were similar to the abnormal tau extracted from paired helical filaments with sodium dodecyl sulfate, also named A68, in molecular mass (68, 64, and 60 kDa), isoelectric point (pI 5.5-6.5), reactivity with anti-tau antibodies, and in requirement for alkaline phosphatase treatment to bind the Tau-1 antibody. Compared to normal tau, the soluble PHF-tau contained 100% more glycine and 35% less lysine residue. The results suggest that besides phosphorylation other types of modification may be involved in differentiating PHF-tau from normal tau.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939196

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Immunocytochemistry of neurofibrillary tangles with antibodies to subregions of tau protein: identification of hidden and cleaved tau epitopes and a new phosphorylation site.

Authors:  D W Dickson; H Ksiezak-Reding; W K Liu; P Davies; A Crowe; S H Yen
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 2.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

3.  Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: differentiation from progressive supranuclear palsy.

Authors:  M B Feany; H Ksiezak-Reding; W K Liu; I Vincent; S H Yen; D W Dickson
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

4.  Atomic force microscopy of paired helical filaments isolated from the autopsied brains of patients with Alzheimer's disease and immunolabeled against microtubule-associated protein tau.

Authors:  M D Ikonomovic; D M Armstrong; S H Yen; C Obcemea; B Vidic
Journal:  Am J Pathol       Date:  1995-08       Impact factor: 4.307

Review 5.  Probing modifications of the neuronal cytoskeleton.

Authors:  L C Doering
Journal:  Mol Neurobiol       Date:  1993 Fall-Winter       Impact factor: 5.590

6.  Detection of a Cdc2-related kinase associated with Alzheimer paired helical filaments.

Authors:  W K Liu; R T Williams; F L Hall; D W Dickson; S H Yen
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

7.  Functional domains on chemically modified tau protein.

Authors:  G A Farías; C Vial; R B Maccioni
Journal:  Cell Mol Neurobiol       Date:  1993-04       Impact factor: 5.046

8.  Immunological characterization of epitopes on tau of Alzheimer's type and chemically modified tau.

Authors:  G Farías; C González-Billault; R B Maccioni
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

9.  Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.

Authors:  S D Yan; X Chen; A M Schmidt; J Brett; G Godman; Y S Zou; C W Scott; C Caputo; T Frappier; M A Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

10.  Heterogeneity of tau proteins in Alzheimer's disease. Evidence for increased expression of an isoform and preferential distribution of a phosphorylated isoform in neurites.

Authors:  W K Liu; D W Dickson; S H Yen
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.